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ABSTRACT
Background: Tuberculosis (TB) is of high public health importance in Malaysia. Sabah State,
located on the island of Borneo, has previously reported a particularly high burden of disease
and faces unique contextual challenges compared with peninsular Malaysia. The aim of this
study is to describe the epidemiology of TB in Sabah to identify risk groups and hotspots of TB
transmission. Methods: We conducted a retrospective review of TB cases notified in Sabah,
Malaysia, between 2012 and 2018. Using data from the state’s ‘myTB’ notification database, we
calculated the case notification rate and described trends in the epidemiology, diagnostic
practices and treatment outcomes of TB in Sabah within this period. The Chi-squared test was
used for determining the difference between two proportions. Results: Between 2012 and 2018
there were 33 193 cases of TB reported in Sabah (128 cases per 100 000 population). We
identified several geographic hotspots, including districts with > 200 cases per 100 000
population per year. TB rates increased with age and were highest in older males. Children <
15 years accounted for only 4.6% of cases. Moderate or advanced disease on chest X-ray and
sputum smear positivity was high (58 and 81% of cases respectively), suggesting frequent late
diagnosis. Multi-drug resistant (MDR) TB prevalence was low (0.3% of TB cases), however,
rapid diagnostic test coverage was low (1.2%) and only 18% of all cases had a positive culture
result. Treatment success was 83% (range: 81–85%) in those with drug-sensitive TB and 36%
(range: 25–45%) in cases of MDR-TB. Conclusion: Between 2012 and 2018, TB notifications in
Sabah State equated to 20% of Malaysia’s total TB notifications, despite Sabah representing
only 10% of Malaysia’s population. We found hotspots of TB in urbanised population hubs and
points of migration, as well as evidence of late presentation and diagnosis. Ensuring universal
health coverage and expansion of GeneXpert® coverage is recommended to reduce barriers to
care and early diagnosis and treatment for TB.
